PAVmed Closes $13.4 Million Common Stock Registered Direct Offering Priced At-the-Market under Nasdaq RulesGlobeNewsWire • 01/08/21
PAVmed Announces Registered Direct Offering of its Common Stock Priced At-the-Market under Nasdaq RulesGlobeNewsWire • 01/06/21
PAVmed Closes Additional $8.1 Million Common Stock Registered Direct OfferingGlobeNewsWire • 12/22/20
PAVmed Announces Pricing of Additional $8.1 Million Common Stock Registered Direct OfferingGlobeNewsWire • 12/18/20
PAVmed's (PAVM) CEO Lishan Aklog on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/18/20
PAVmed Reports Third Quarter 2020 Financial Results and Provides Business UpdateGlobeNewsWire • 11/17/20
PAVmed to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference on September 15, 2020GlobeNewsWire • 09/08/20
PAVmed Inc. (PAVM) CEO Lishan Aklog on Q2 2020 Results and Business Update - Earnings Call TranscriptSeeking Alpha • 08/19/20
PAVmed Reports Second Quarter 2020 Financial Results and Provides Business UpdateGlobeNewsWire • 08/18/20
Founder and Former Chairman & CEO of Exact Sciences Stanley Lapidus Joins PAVmed Subsidiary Lucid Diagnostics as Strategic AdvisorGlobeNewsWire • 06/15/20
PAVmed Subsidiary Lucid Diagnostics Receives Preliminary Payment Determination for EsoGuard™ Esophageal DNA TestGlobeNewsWire • 06/11/20
PAVmed Inc. (PAVM) CEO Lishan Aklog on Q1 2020 Results and Business Update - Earnings Call TranscriptSeeking Alpha • 05/22/20
PAVmed Reports Preliminary First Quarter 2020 Financial Results and Provides Business UpdateGlobeNewsWire • 05/21/20
PAVmed: Small Medical Device Maker With New FDA Approval And Multiple CatalystsSeeking Alpha • 04/24/20
PAVmed Receives FDA 510(k) Clearance for its CarpX™ Minimally Invasive Carpal Tunnel DeviceGlobeNewsWire • 04/21/20
PAVmed Inc. (PAVM) CEO Lishan Aklog on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 04/10/20